SNAI1 and familial pancreatic carcinoma: This is the case of the phase I trial performed in advanced solid tumor patients that demonstrated the effectiveness of MRX34 (Beg et al., 2017), a liposomal miR‐34a mimic, which inhibits Snail1‐mediated EMT and the NOTCH pathway in pancreatic cancer cell lines (Tang et al., 2017).